nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—LIPF—digestive system—Crohn's disease	0.0338	0.173	CbGeAlD
Orlistat—Dyschezia—Mesalazine—Crohn's disease	0.0315	0.0713	CcSEcCtD
Orlistat—PNLIP—mouth—Crohn's disease	0.0271	0.139	CbGeAlD
Orlistat—Faeces discoloured—Mesalazine—Crohn's disease	0.0171	0.0388	CcSEcCtD
Orlistat—PLA2G7—mammalian vulva—Crohn's disease	0.0155	0.0796	CbGeAlD
Orlistat—ABHD16A—mammalian vulva—Crohn's disease	0.0146	0.0747	CbGeAlD
Orlistat—Anal pruritus—Mesalazine—Crohn's disease	0.0142	0.0321	CcSEcCtD
Orlistat—PLA2G7—lymphoid tissue—Crohn's disease	0.0138	0.0707	CbGeAlD
Orlistat—ABHD12—mammalian vulva—Crohn's disease	0.0137	0.07	CbGeAlD
Orlistat—PNLIP—digestive system—Crohn's disease	0.012	0.0614	CbGeAlD
Orlistat—FASN—mammalian vulva—Crohn's disease	0.0115	0.0588	CbGeAlD
Orlistat—Diverticulitis—Azathioprine—Crohn's disease	0.01	0.0227	CcSEcCtD
Orlistat—Reaction gastrointestinal—Azathioprine—Crohn's disease	0.00978	0.0221	CcSEcCtD
Orlistat—DAGLB—lymph node—Crohn's disease	0.00964	0.0494	CbGeAlD
Orlistat—Abdominal pain lower—Mesalazine—Crohn's disease	0.00935	0.0211	CcSEcCtD
Orlistat—PLA2G7—lymph node—Crohn's disease	0.00779	0.0399	CbGeAlD
Orlistat—ABHD16A—lymph node—Crohn's disease	0.00731	0.0374	CbGeAlD
Orlistat—Obesity—Prednisone—Crohn's disease	0.00721	0.0163	CcSEcCtD
Orlistat—Pruritus genital—Mesalazine—Crohn's disease	0.00712	0.0161	CcSEcCtD
Orlistat—ABHD12—lymph node—Crohn's disease	0.00685	0.0351	CbGeAlD
Orlistat—Proctalgia—Mesalazine—Crohn's disease	0.00634	0.0143	CcSEcCtD
Orlistat—Nephropathy—Mesalazine—Crohn's disease	0.00625	0.0141	CcSEcCtD
Orlistat—PLA2G4A—smooth muscle tissue—Crohn's disease	0.00613	0.0314	CbGeAlD
Orlistat—Faecal incontinence—Mesalazine—Crohn's disease	0.00589	0.0133	CcSEcCtD
Orlistat—FASN—lymph node—Crohn's disease	0.00575	0.0294	CbGeAlD
Orlistat—PLA2G4A—mammalian vulva—Crohn's disease	0.00551	0.0282	CbGeAlD
Orlistat—Anorectal discomfort—Mesalazine—Crohn's disease	0.00544	0.0123	CcSEcCtD
Orlistat—Cholecystitis—Mesalazine—Crohn's disease	0.00518	0.0117	CcSEcCtD
Orlistat—Gastrointestinal symptom NOS—Mesalazine—Crohn's disease	0.00506	0.0114	CcSEcCtD
Orlistat—Haemorrhoids—Mesalazine—Crohn's disease	0.00506	0.0114	CcSEcCtD
Orlistat—Neoplasm—Mercaptopurine—Crohn's disease	0.00495	0.0112	CcSEcCtD
Orlistat—Cholelithiasis—Mesalazine—Crohn's disease	0.00478	0.0108	CcSEcCtD
Orlistat—Nail disorder—Mesalazine—Crohn's disease	0.00458	0.0104	CcSEcCtD
Orlistat—Upset stomach—Mesalazine—Crohn's disease	0.00454	0.0103	CcSEcCtD
Orlistat—Epilepsy—Prednisone—Crohn's disease	0.00414	0.00936	CcSEcCtD
Orlistat—Breast disorder—Mercaptopurine—Crohn's disease	0.00359	0.00813	CcSEcCtD
Orlistat—Blood disorder—Mesalazine—Crohn's disease	0.00356	0.00805	CcSEcCtD
Orlistat—Acne—Mesalazine—Crohn's disease	0.00353	0.00799	CcSEcCtD
Orlistat—Amenorrhoea—Mesalazine—Crohn's disease	0.00338	0.00765	CcSEcCtD
Orlistat—Pancreatitis—Mercaptopurine—Crohn's disease	0.00337	0.00762	CcSEcCtD
Orlistat—Rectal haemorrhage—Mesalazine—Crohn's disease	0.00329	0.00745	CcSEcCtD
Orlistat—Dysmenorrhoea—Mesalazine—Crohn's disease	0.00327	0.0074	CcSEcCtD
Orlistat—Arthropathy—Mesalazine—Crohn's disease	0.00327	0.0074	CcSEcCtD
Orlistat—Vaginal inflammation—Mesalazine—Crohn's disease	0.00297	0.00673	CcSEcCtD
Orlistat—Neoplasm—Azathioprine—Crohn's disease	0.00295	0.00667	CcSEcCtD
Orlistat—Eructation—Mesalazine—Crohn's disease	0.00292	0.00661	CcSEcCtD
Orlistat—Hepatobiliary disease—Mercaptopurine—Crohn's disease	0.0029	0.00656	CcSEcCtD
Orlistat—Menstruation irregular—Prednisone—Crohn's disease	0.00284	0.00643	CcSEcCtD
Orlistat—Vaginal infection—Mesalazine—Crohn's disease	0.00281	0.00635	CcSEcCtD
Orlistat—PLA2G4A—lymph node—Crohn's disease	0.00276	0.0141	CbGeAlD
Orlistat—Cramps of lower extremities—Mesalazine—Crohn's disease	0.00273	0.00618	CcSEcCtD
Orlistat—Multiple fractures—Prednisone—Crohn's disease	0.00271	0.00612	CcSEcCtD
Orlistat—Fracture—Prednisone—Crohn's disease	0.00271	0.00612	CcSEcCtD
Orlistat—Hepatic failure—Azathioprine—Crohn's disease	0.00264	0.00596	CcSEcCtD
Orlistat—Immune system disorder—Mercaptopurine—Crohn's disease	0.00249	0.00562	CcSEcCtD
Orlistat—Hypothyroidism—Prednisone—Crohn's disease	0.00245	0.00554	CcSEcCtD
Orlistat—Alopecia—Mercaptopurine—Crohn's disease	0.00243	0.0055	CcSEcCtD
Orlistat—Eczema—Mesalazine—Crohn's disease	0.0024	0.00543	CcSEcCtD
Orlistat—Hepatic failure—Mesalazine—Crohn's disease	0.0024	0.00543	CcSEcCtD
Orlistat—Malnutrition—Mercaptopurine—Crohn's disease	0.0024	0.00542	CcSEcCtD
Orlistat—Increased appetite—Mesalazine—Crohn's disease	0.0023	0.0052	CcSEcCtD
Orlistat—Thirst—Mesalazine—Crohn's disease	0.00227	0.00513	CcSEcCtD
Orlistat—Dermatitis bullous—Mesalazine—Crohn's disease	0.00226	0.00511	CcSEcCtD
Orlistat—Arthritis—Mesalazine—Crohn's disease	0.00222	0.00502	CcSEcCtD
Orlistat—Osteoarthritis—Mesalazine—Crohn's disease	0.00216	0.00488	CcSEcCtD
Orlistat—PLA2G4A—Dexamethasone—Prednisone—Crohn's disease	0.00211	0.5	CbGdCrCtD
Orlistat—PLA2G4A—Betamethasone—Prednisone—Crohn's disease	0.00211	0.5	CbGdCrCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.00202	0.00458	CcSEcCtD
Orlistat—Pancreatitis—Azathioprine—Crohn's disease	0.00201	0.00454	CcSEcCtD
Orlistat—Dry skin—Mesalazine—Crohn's disease	0.00198	0.00447	CcSEcCtD
Orlistat—Abdominal pain upper—Mesalazine—Crohn's disease	0.00197	0.00446	CcSEcCtD
Orlistat—Abdominal discomfort—Azathioprine—Crohn's disease	0.00196	0.00444	CcSEcCtD
Orlistat—Oedema—Mercaptopurine—Crohn's disease	0.00195	0.00442	CcSEcCtD
Orlistat—Breast disorder—Mesalazine—Crohn's disease	0.00195	0.00441	CcSEcCtD
Orlistat—Cramp muscle—Mesalazine—Crohn's disease	0.00194	0.0044	CcSEcCtD
Orlistat—Gastritis—Mesalazine—Crohn's disease	0.00191	0.00432	CcSEcCtD
Orlistat—Skin disorder—Mercaptopurine—Crohn's disease	0.0019	0.00429	CcSEcCtD
Orlistat—Abdominal distension—Mesalazine—Crohn's disease	0.00188	0.00425	CcSEcCtD
Orlistat—Acne—Prednisone—Crohn's disease	0.00187	0.00423	CcSEcCtD
Orlistat—Influenza—Mesalazine—Crohn's disease	0.00187	0.00422	CcSEcCtD
Orlistat—Asthma—Mesalazine—Crohn's disease	0.00187	0.00422	CcSEcCtD
Orlistat—Bronchospasm—Mesalazine—Crohn's disease	0.00184	0.00415	CcSEcCtD
Orlistat—Pancreatitis—Mesalazine—Crohn's disease	0.00183	0.00414	CcSEcCtD
Orlistat—Infestation NOS—Azathioprine—Crohn's disease	0.00183	0.00413	CcSEcCtD
Orlistat—Infestation—Azathioprine—Crohn's disease	0.00183	0.00413	CcSEcCtD
Orlistat—Amenorrhoea—Prednisone—Crohn's disease	0.00179	0.00405	CcSEcCtD
Orlistat—Abdominal discomfort—Mesalazine—Crohn's disease	0.00179	0.00404	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.00178	0.00403	CcSEcCtD
Orlistat—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.00173	0.00392	CcSEcCtD
Orlistat—Arthropathy—Prednisone—Crohn's disease	0.00173	0.00391	CcSEcCtD
Orlistat—Hepatobiliary disease—Azathioprine—Crohn's disease	0.00173	0.00391	CcSEcCtD
Orlistat—Decreased appetite—Mercaptopurine—Crohn's disease	0.0017	0.00384	CcSEcCtD
Orlistat—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00169	0.00382	CcSEcCtD
Orlistat—Infestation NOS—Mesalazine—Crohn's disease	0.00166	0.00376	CcSEcCtD
Orlistat—Infestation—Mesalazine—Crohn's disease	0.00166	0.00376	CcSEcCtD
Orlistat—Depression—Mesalazine—Crohn's disease	0.00166	0.00375	CcSEcCtD
Orlistat—Haemoglobin—Azathioprine—Crohn's disease	0.00165	0.00373	CcSEcCtD
Orlistat—Haemorrhage—Azathioprine—Crohn's disease	0.00164	0.00371	CcSEcCtD
Orlistat—Renal failure—Mesalazine—Crohn's disease	0.00164	0.0037	CcSEcCtD
Orlistat—Neuropathy peripheral—Mesalazine—Crohn's disease	0.00163	0.00369	CcSEcCtD
Orlistat—Urinary tract infection—Mesalazine—Crohn's disease	0.00162	0.00366	CcSEcCtD
Orlistat—CYP3A4—digestive system—Crohn's disease	0.0016	0.00817	CbGeAlD
Orlistat—Hepatobiliary disease—Mesalazine—Crohn's disease	0.00157	0.00356	CcSEcCtD
Orlistat—Sinusitis—Mesalazine—Crohn's disease	0.00156	0.00353	CcSEcCtD
Orlistat—Body temperature increased—Mercaptopurine—Crohn's disease	0.00155	0.00349	CcSEcCtD
Orlistat—Haemoglobin—Mesalazine—Crohn's disease	0.0015	0.00339	CcSEcCtD
Orlistat—Hepatitis—Mesalazine—Crohn's disease	0.00149	0.00338	CcSEcCtD
Orlistat—Haemorrhage—Mesalazine—Crohn's disease	0.00149	0.00338	CcSEcCtD
Orlistat—Pharyngitis—Mesalazine—Crohn's disease	0.00148	0.00335	CcSEcCtD
Orlistat—Immune system disorder—Azathioprine—Crohn's disease	0.00148	0.00335	CcSEcCtD
Orlistat—Mediastinal disorder—Azathioprine—Crohn's disease	0.00148	0.00334	CcSEcCtD
Orlistat—Urinary tract disorder—Mesalazine—Crohn's disease	0.00147	0.00334	CcSEcCtD
Orlistat—Oedema peripheral—Mesalazine—Crohn's disease	0.00147	0.00333	CcSEcCtD
Orlistat—Urethral disorder—Mesalazine—Crohn's disease	0.00146	0.00331	CcSEcCtD
Orlistat—Alopecia—Azathioprine—Crohn's disease	0.00145	0.00328	CcSEcCtD
Orlistat—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00144	0.00326	CcSEcCtD
Orlistat—Immune system disorder—Mesalazine—Crohn's disease	0.00135	0.00305	CcSEcCtD
Orlistat—Mediastinal disorder—Mesalazine—Crohn's disease	0.00135	0.00304	CcSEcCtD
Orlistat—Diarrhoea—Mercaptopurine—Crohn's disease	0.00134	0.00302	CcSEcCtD
Orlistat—Ill-defined disorder—Azathioprine—Crohn's disease	0.00132	0.00299	CcSEcCtD
Orlistat—Alopecia—Mesalazine—Crohn's disease	0.00132	0.00298	CcSEcCtD
Orlistat—Diabetes mellitus—Prednisone—Crohn's disease	0.00131	0.00297	CcSEcCtD
Orlistat—Mental disorder—Mesalazine—Crohn's disease	0.00131	0.00296	CcSEcCtD
Orlistat—Malaise—Azathioprine—Crohn's disease	0.00129	0.00291	CcSEcCtD
Orlistat—Flatulence—Mesalazine—Crohn's disease	0.00128	0.0029	CcSEcCtD
Orlistat—Dysgeusia—Mesalazine—Crohn's disease	0.00127	0.00288	CcSEcCtD
Orlistat—Back pain—Mesalazine—Crohn's disease	0.00126	0.00284	CcSEcCtD
Orlistat—Muscle spasms—Mesalazine—Crohn's disease	0.00125	0.00283	CcSEcCtD
Orlistat—Vomiting—Mercaptopurine—Crohn's disease	0.00124	0.00281	CcSEcCtD
Orlistat—Rash—Mercaptopurine—Crohn's disease	0.00123	0.00279	CcSEcCtD
Orlistat—Dermatitis—Mercaptopurine—Crohn's disease	0.00123	0.00278	CcSEcCtD
Orlistat—Vision blurred—Mesalazine—Crohn's disease	0.00123	0.00277	CcSEcCtD
Orlistat—Increased appetite—Prednisone—Crohn's disease	0.00122	0.00275	CcSEcCtD
Orlistat—Myalgia—Azathioprine—Crohn's disease	0.00121	0.00275	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.00121	0.00273	CcSEcCtD
Orlistat—Ill-defined disorder—Mesalazine—Crohn's disease	0.00121	0.00273	CcSEcCtD
Orlistat—Discomfort—Azathioprine—Crohn's disease	0.0012	0.00271	CcSEcCtD
Orlistat—Angioedema—Mesalazine—Crohn's disease	0.00119	0.00269	CcSEcCtD
Orlistat—Malaise—Mesalazine—Crohn's disease	0.00117	0.00265	CcSEcCtD
Orlistat—Vertigo—Mesalazine—Crohn's disease	0.00117	0.00264	CcSEcCtD
Orlistat—Nausea—Mercaptopurine—Crohn's disease	0.00116	0.00263	CcSEcCtD
Orlistat—Infection—Azathioprine—Crohn's disease	0.00116	0.00262	CcSEcCtD
Orlistat—Palpitations—Mesalazine—Crohn's disease	0.00115	0.0026	CcSEcCtD
Orlistat—Osteoarthritis—Prednisone—Crohn's disease	0.00114	0.00258	CcSEcCtD
Orlistat—Cough—Mesalazine—Crohn's disease	0.00113	0.00257	CcSEcCtD
Orlistat—Skin disorder—Azathioprine—Crohn's disease	0.00113	0.00256	CcSEcCtD
Orlistat—Chest pain—Mesalazine—Crohn's disease	0.00111	0.0025	CcSEcCtD
Orlistat—Myalgia—Mesalazine—Crohn's disease	0.00111	0.0025	CcSEcCtD
Orlistat—Anxiety—Mesalazine—Crohn's disease	0.0011	0.00249	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.0011	0.00249	CcSEcCtD
Orlistat—Discomfort—Mesalazine—Crohn's disease	0.00109	0.00247	CcSEcCtD
Orlistat—Dry mouth—Mesalazine—Crohn's disease	0.00108	0.00245	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.00106	0.0024	CcSEcCtD
Orlistat—Anaphylactic shock—Mesalazine—Crohn's disease	0.00106	0.0024	CcSEcCtD
Orlistat—Oedema—Mesalazine—Crohn's disease	0.00106	0.0024	CcSEcCtD
Orlistat—DAGLA—Hemostasis—ITGA4—Crohn's disease	0.00106	0.00296	CbGpPWpGaD
Orlistat—Infection—Mesalazine—Crohn's disease	0.00105	0.00238	CcSEcCtD
Orlistat—Dry skin—Prednisone—Crohn's disease	0.00105	0.00237	CcSEcCtD
Orlistat—Nervous system disorder—Mesalazine—Crohn's disease	0.00104	0.00235	CcSEcCtD
Orlistat—Hypokalaemia—Prednisone—Crohn's disease	0.00104	0.00235	CcSEcCtD
Orlistat—DAGLB—Hemostasis—IL3—Crohn's disease	0.00103	0.00288	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—IL3—Crohn's disease	0.00103	0.00288	CbGpPWpGaD
Orlistat—Skin disorder—Mesalazine—Crohn's disease	0.00103	0.00233	CcSEcCtD
Orlistat—Hyperhidrosis—Mesalazine—Crohn's disease	0.00103	0.00232	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—MLN—Crohn's disease	0.00102	0.00284	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MLN—Crohn's disease	0.00102	0.00284	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—ALB—Crohn's disease	0.00102	0.00283	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—ALB—Crohn's disease	0.00102	0.00283	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	0.00101	0.00282	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	0.00101	0.00282	CbGpPWpGaD
Orlistat—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.00101	0.00227	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—SMAD3—Crohn's disease	0.001	0.0028	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—RASGRP1—Crohn's disease	0.000999	0.00279	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—RASGRP1—Crohn's disease	0.000999	0.00279	CbGpPWpGaD
Orlistat—Abdominal distension—Prednisone—Crohn's disease	0.000994	0.00225	CcSEcCtD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—Crohn's disease	0.000976	0.00272	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.00097	0.00271	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—PTPN2—Crohn's disease	0.00097	0.00271	CbGpPWpGaD
Orlistat—Pancreatitis—Prednisone—Crohn's disease	0.000968	0.00219	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000967	0.00219	CcSEcCtD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	0.000965	0.00269	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	0.000965	0.00269	CbGpPWpGaD
Orlistat—PNLIP—Disease—RSPO3—Crohn's disease	0.000962	0.00269	CbGpPWpGaD
Orlistat—Sweating increased—Prednisone—Crohn's disease	0.000961	0.00217	CcSEcCtD
Orlistat—Feeling abnormal—Azathioprine—Crohn's disease	0.00096	0.00217	CcSEcCtD
Orlistat—Insomnia—Mesalazine—Crohn's disease	0.00096	0.00217	CcSEcCtD
Orlistat—Paraesthesia—Mesalazine—Crohn's disease	0.000953	0.00215	CcSEcCtD
Orlistat—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000952	0.00215	CcSEcCtD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	0.000944	0.00263	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	0.000944	0.00263	CbGpPWpGaD
Orlistat—Dyspepsia—Mesalazine—Crohn's disease	0.000934	0.00211	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—TAGAP—Crohn's disease	0.00093	0.0026	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TAGAP—Crohn's disease	0.00093	0.0026	CbGpPWpGaD
Orlistat—Decreased appetite—Mesalazine—Crohn's disease	0.000922	0.00209	CcSEcCtD
Orlistat—PNLIP—Metabolism—PLA2G4F—Crohn's disease	0.000922	0.00257	CbGpPWpGaD
Orlistat—Abdominal pain—Azathioprine—Crohn's disease	0.000921	0.00208	CcSEcCtD
Orlistat—Body temperature increased—Azathioprine—Crohn's disease	0.000921	0.00208	CcSEcCtD
Orlistat—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000916	0.00207	CcSEcCtD
Orlistat—Fatigue—Mesalazine—Crohn's disease	0.000915	0.00207	CcSEcCtD
Orlistat—PNLIP—Disease—SEL1L—Crohn's disease	0.000912	0.00255	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.000909	0.00254	CbGpPWpGaD
Orlistat—Pain—Mesalazine—Crohn's disease	0.000907	0.00205	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—ACKR2—Crohn's disease	0.000889	0.00248	CbGpPWpGaD
Orlistat—Depression—Prednisone—Crohn's disease	0.000878	0.00198	CcSEcCtD
Orlistat—Feeling abnormal—Mesalazine—Crohn's disease	0.000874	0.00198	CcSEcCtD
Orlistat—DAGLB—GPCR downstream signaling—CCR6—Crohn's disease	0.000871	0.00243	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—CCR6—Crohn's disease	0.000871	0.00243	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Mesalazine—Crohn's disease	0.000868	0.00196	CcSEcCtD
Orlistat—Neuropathy peripheral—Prednisone—Crohn's disease	0.000863	0.00195	CcSEcCtD
Orlistat—Hypersensitivity—Azathioprine—Crohn's disease	0.000858	0.00194	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—MLN—Crohn's disease	0.000843	0.00235	CbGpPWpGaD
Orlistat—Urticaria—Mesalazine—Crohn's disease	0.000843	0.00191	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—F5—Crohn's disease	0.000841	0.00235	CbGpPWpGaD
Orlistat—Abdominal pain—Mesalazine—Crohn's disease	0.000839	0.0019	CcSEcCtD
Orlistat—Body temperature increased—Mesalazine—Crohn's disease	0.000839	0.0019	CcSEcCtD
Orlistat—PNLIP—Disease—LTF—Crohn's disease	0.000818	0.00228	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RSPO3—Crohn's disease	0.000813	0.00227	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—RSPO3—Crohn's disease	0.000813	0.00227	CbGpPWpGaD
Orlistat—Diarrhoea—Azathioprine—Crohn's disease	0.000797	0.0018	CcSEcCtD
Orlistat—Haemoglobin—Prednisone—Crohn's disease	0.000794	0.0018	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—CCR6—Crohn's disease	0.000791	0.00221	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CCR6—Crohn's disease	0.000791	0.00221	CbGpPWpGaD
Orlistat—Haemorrhage—Prednisone—Crohn's disease	0.00079	0.00179	CcSEcCtD
Orlistat—PNLIP—Metabolism—MTMR3—Crohn's disease	0.000784	0.00219	CbGpPWpGaD
Orlistat—Hypersensitivity—Mesalazine—Crohn's disease	0.000782	0.00177	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—SEL1L—Crohn's disease	0.000771	0.00215	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SEL1L—Crohn's disease	0.000771	0.00215	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TAGAP—Crohn's disease	0.000771	0.00215	CbGpPWpGaD
Orlistat—Dizziness—Azathioprine—Crohn's disease	0.00077	0.00174	CcSEcCtD
Orlistat—DAGLA—GPCR downstream signaling—PTGER4—Crohn's disease	0.000767	0.00214	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—PTGER4—Crohn's disease	0.000767	0.00214	CbGpPWpGaD
Orlistat—Asthenia—Mesalazine—Crohn's disease	0.000761	0.00172	CcSEcCtD
Orlistat—Pruritus—Mesalazine—Crohn's disease	0.000751	0.0017	CcSEcCtD
Orlistat—Vomiting—Azathioprine—Crohn's disease	0.000741	0.00167	CcSEcCtD
Orlistat—Rash—Azathioprine—Crohn's disease	0.000734	0.00166	CcSEcCtD
Orlistat—Dermatitis—Azathioprine—Crohn's disease	0.000734	0.00166	CcSEcCtD
Orlistat—PLA2G4A—Arachidonic acid metabolism—PTGS2—Crohn's disease	0.000734	0.00205	CbGpPWpGaD
Orlistat—Headache—Azathioprine—Crohn's disease	0.00073	0.00165	CcSEcCtD
Orlistat—Diarrhoea—Mesalazine—Crohn's disease	0.000726	0.00164	CcSEcCtD
Orlistat—DAGLB—Hemostasis—IL2RA—Crohn's disease	0.000724	0.00202	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—IL2RA—Crohn's disease	0.000724	0.00202	CbGpPWpGaD
Orlistat—Immune system disorder—Prednisone—Crohn's disease	0.000714	0.00161	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—CCR9—Crohn's disease	0.000705	0.00197	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCR9—Crohn's disease	0.000705	0.00197	CbGpPWpGaD
Orlistat—Dizziness—Mesalazine—Crohn's disease	0.000702	0.00159	CcSEcCtD
Orlistat—Alopecia—Prednisone—Crohn's disease	0.000698	0.00158	CcSEcCtD
Orlistat—PLA2G4A—PDGF Pathway—STAT3—Crohn's disease	0.000698	0.00195	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—PTGER4—Crohn's disease	0.000696	0.00194	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—PTGER4—Crohn's disease	0.000696	0.00194	CbGpPWpGaD
Orlistat—Mental disorder—Prednisone—Crohn's disease	0.000692	0.00157	CcSEcCtD
Orlistat—Nausea—Azathioprine—Crohn's disease	0.000692	0.00156	CcSEcCtD
Orlistat—Malnutrition—Prednisone—Crohn's disease	0.000688	0.00156	CcSEcCtD
Orlistat—FASN—Disease—RSPO3—Crohn's disease	0.000681	0.0019	CbGpPWpGaD
Orlistat—Vomiting—Mesalazine—Crohn's disease	0.000675	0.00153	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—RSPO3—Crohn's disease	0.000674	0.00188	CbGpPWpGaD
Orlistat—Rash—Mesalazine—Crohn's disease	0.000669	0.00151	CcSEcCtD
Orlistat—Dermatitis—Mesalazine—Crohn's disease	0.000668	0.00151	CcSEcCtD
Orlistat—Headache—Mesalazine—Crohn's disease	0.000665	0.0015	CcSEcCtD
Orlistat—PNLIP—Disease—GCKR—Crohn's disease	0.00066	0.00184	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—GPR65—Crohn's disease	0.000656	0.00183	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—GPR65—Crohn's disease	0.000656	0.00183	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—IL3—Crohn's disease	0.000653	0.00182	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—IL3—Crohn's disease	0.000653	0.00182	CbGpPWpGaD
Orlistat—FASN—Metabolism—PLA2G4F—Crohn's disease	0.000652	0.00182	CbGpPWpGaD
Orlistat—Vision blurred—Prednisone—Crohn's disease	0.000648	0.00147	CcSEcCtD
Orlistat—PLA2G4A—Endothelins—JAK2—Crohn's disease	0.000648	0.00181	CbGpPWpGaD
Orlistat—FASN—Disease—SEL1L—Crohn's disease	0.000645	0.0018	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SEL1L—Crohn's disease	0.000639	0.00178	CbGpPWpGaD
Orlistat—Ill-defined disorder—Prednisone—Crohn's disease	0.000638	0.00144	CcSEcCtD
Orlistat—DAGLB—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000632	0.00176	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000632	0.00176	CbGpPWpGaD
Orlistat—Nausea—Mesalazine—Crohn's disease	0.00063	0.00143	CcSEcCtD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000629	0.00175	CbGpPWpGaD
Orlistat—Angioedema—Prednisone—Crohn's disease	0.000628	0.00142	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—JAK2—Crohn's disease	0.000624	0.00174	CbGpPWpGaD
Orlistat—Malaise—Prednisone—Crohn's disease	0.00062	0.0014	CcSEcCtD
Orlistat—Vertigo—Prednisone—Crohn's disease	0.000618	0.0014	CcSEcCtD
Orlistat—PNLIP—Metabolism—FADS1—Crohn's disease	0.000611	0.0017	CbGpPWpGaD
Orlistat—Convulsion—Prednisone—Crohn's disease	0.000596	0.00135	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—IL3—Crohn's disease	0.000593	0.00165	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL3—Crohn's disease	0.000593	0.00165	CbGpPWpGaD
Orlistat—Myalgia—Prednisone—Crohn's disease	0.000586	0.00132	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—CCR9—Crohn's disease	0.000584	0.00163	CbGpPWpGaD
Orlistat—Anxiety—Prednisone—Crohn's disease	0.000583	0.00132	CcSEcCtD
Orlistat—PNLIP—Disease—SLC11A1—Crohn's disease	0.000583	0.00163	CbGpPWpGaD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000581	0.00132	CcSEcCtD
Orlistat—FASN—Disease—LTF—Crohn's disease	0.000579	0.00162	CbGpPWpGaD
Orlistat—Discomfort—Prednisone—Crohn's disease	0.000579	0.00131	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—RASGRP1—Crohn's disease	0.000574	0.0016	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—RASGRP1—Crohn's disease	0.000574	0.0016	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—GPX4—Crohn's disease	0.000572	0.0016	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—IL3—Crohn's disease	0.000567	0.00158	CbGpPWpGaD
Orlistat—Oedema—Prednisone—Crohn's disease	0.000561	0.00127	CcSEcCtD
Orlistat—Anaphylactic shock—Prednisone—Crohn's disease	0.000561	0.00127	CcSEcCtD
Orlistat—Infection—Prednisone—Crohn's disease	0.000558	0.00126	CcSEcCtD
Orlistat—FASN—Metabolism—MTMR3—Crohn's disease	0.000555	0.00155	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—GCKR—Crohn's disease	0.000552	0.00154	CbGpPWpGaD
Orlistat—Nervous system disorder—Prednisone—Crohn's disease	0.00055	0.00124	CcSEcCtD
Orlistat—Skin disorder—Prednisone—Crohn's disease	0.000545	0.00123	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—GPR65—Crohn's disease	0.000543	0.00152	CbGpPWpGaD
Orlistat—Hyperhidrosis—Prednisone—Crohn's disease	0.000543	0.00123	CcSEcCtD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.000534	0.00149	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—ALB—Crohn's disease	0.000523	0.00146	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—ALB—Crohn's disease	0.000523	0.00146	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000511	0.00116	CcSEcCtD
Orlistat—Insomnia—Prednisone—Crohn's disease	0.000508	0.00115	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—IL3—Crohn's disease	0.000504	0.00141	CbGpPWpGaD
Orlistat—Paraesthesia—Prednisone—Crohn's disease	0.000504	0.00114	CcSEcCtD
Orlistat—PNLIP—Disease—HSPA1B—Crohn's disease	0.0005	0.00139	CbGpPWpGaD
Orlistat—PNLIP—Disease—RBX1—Crohn's disease	0.0005	0.00139	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	0.000495	0.00138	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	0.000495	0.00138	CbGpPWpGaD
Orlistat—Dyspepsia—Prednisone—Crohn's disease	0.000494	0.00112	CcSEcCtD
Orlistat—Decreased appetite—Prednisone—Crohn's disease	0.000488	0.0011	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—RASGRP1—Crohn's disease	0.000488	0.00136	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—JAK2—Crohn's disease	0.000486	0.00136	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—JAK2—Crohn's disease	0.000486	0.00136	CbGpPWpGaD
Orlistat—Fatigue—Prednisone—Crohn's disease	0.000484	0.00109	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—CCR6—Crohn's disease	0.000467	0.0013	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCR6—Crohn's disease	0.000467	0.0013	CbGpPWpGaD
Orlistat—FASN—Disease—GCKR—Crohn's disease	0.000467	0.0013	CbGpPWpGaD
Orlistat—Feeling abnormal—Prednisone—Crohn's disease	0.000463	0.00105	CcSEcCtD
Orlistat—PLA2G7—Metabolism of proteins—CXCL8—Crohn's disease	0.000461	0.00129	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Prednisone—Crohn's disease	0.000459	0.00104	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—STAT3—Crohn's disease	0.000458	0.00128	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—IL2RA—Crohn's disease	0.000457	0.00128	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—IL2RA—Crohn's disease	0.000457	0.00128	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—ACKR2—Crohn's disease	0.000457	0.00128	CbGpPWpGaD
Orlistat—Urticaria—Prednisone—Crohn's disease	0.000446	0.00101	CcSEcCtD
Orlistat—Body temperature increased—Prednisone—Crohn's disease	0.000444	0.001	CcSEcCtD
Orlistat—Abdominal pain—Prednisone—Crohn's disease	0.000444	0.001	CcSEcCtD
Orlistat—PNLIP—Disease—UBE2D1—Crohn's disease	0.000438	0.00122	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—F5—Crohn's disease	0.000434	0.00121	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MLN—Crohn's disease	0.000433	0.00121	CbGpPWpGaD
Orlistat—FASN—Metabolism—FADS1—Crohn's disease	0.000432	0.00121	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RBX1—Crohn's disease	0.000422	0.00118	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—RBX1—Crohn's disease	0.000422	0.00118	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000416	0.00116	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL2RA—Crohn's disease	0.000415	0.00116	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL2RA—Crohn's disease	0.000415	0.00116	CbGpPWpGaD
Orlistat—Hypersensitivity—Prednisone—Crohn's disease	0.000414	0.000935	CcSEcCtD
Orlistat—FASN—Disease—SLC11A1—Crohn's disease	0.000413	0.00115	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PTGER4—Crohn's disease	0.000411	0.00115	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PTGER4—Crohn's disease	0.000411	0.00115	CbGpPWpGaD
Orlistat—FASN—Metabolism—GPX4—Crohn's disease	0.000405	0.00113	CbGpPWpGaD
Orlistat—Asthenia—Prednisone—Crohn's disease	0.000403	0.000911	CcSEcCtD
Orlistat—Pruritus—Prednisone—Crohn's disease	0.000397	0.000898	CcSEcCtD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	0.000395	0.0011	CbGpPWpGaD
Orlistat—FASN—Metabolism—GCKR—Crohn's disease	0.000391	0.00109	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.00039	0.00109	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCR6—Crohn's disease	0.000387	0.00108	CbGpPWpGaD
Orlistat—Diarrhoea—Prednisone—Crohn's disease	0.000384	0.000869	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—JAK2—Crohn's disease	0.000375	0.00105	CbGpPWpGaD
Orlistat—Dizziness—Prednisone—Crohn's disease	0.000371	0.000839	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—UBE2D1—Crohn's disease	0.00037	0.00103	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—UBE2D1—Crohn's disease	0.00037	0.00103	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RIPK2—Crohn's disease	0.000359	0.001	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—RIPK2—Crohn's disease	0.000359	0.001	CbGpPWpGaD
Orlistat—Vomiting—Prednisone—Crohn's disease	0.000357	0.000807	CcSEcCtD
Orlistat—Rash—Prednisone—Crohn's disease	0.000354	0.0008	CcSEcCtD
Orlistat—FASN—Disease—RBX1—Crohn's disease	0.000354	0.000987	CbGpPWpGaD
Orlistat—FASN—Disease—HSPA1B—Crohn's disease	0.000354	0.000987	CbGpPWpGaD
Orlistat—Dermatitis—Prednisone—Crohn's disease	0.000354	0.0008	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—IL2RA—Crohn's disease	0.000353	0.000986	CbGpPWpGaD
Orlistat—Headache—Prednisone—Crohn's disease	0.000352	0.000795	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—IL3—Crohn's disease	0.00035	0.000977	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL3—Crohn's disease	0.00035	0.000977	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—RBX1—Crohn's disease	0.00035	0.000977	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	0.000345	0.000964	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PTGER4—Crohn's disease	0.000341	0.000951	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—RASGRP1—Crohn's disease	0.000339	0.000945	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RASGRP1—Crohn's disease	0.000339	0.000945	CbGpPWpGaD
Orlistat—Nausea—Prednisone—Crohn's disease	0.000333	0.000754	CcSEcCtD
Orlistat—PNLIP—Disease—SMAD3—Crohn's disease	0.000314	0.000875	CbGpPWpGaD
Orlistat—FASN—Disease—UBE2D1—Crohn's disease	0.00031	0.000865	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—JAK2—Crohn's disease	0.000307	0.000858	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—JAK2—Crohn's disease	0.000307	0.000858	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—UBE2D1—Crohn's disease	0.000307	0.000857	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SOCS1—Crohn's disease	0.000307	0.000857	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SOCS1—Crohn's disease	0.000307	0.000857	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCR9—Crohn's disease	0.0003	0.000838	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—RIPK2—Crohn's disease	0.000298	0.000831	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—TYK2—Crohn's disease	0.000293	0.000817	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—TYK2—Crohn's disease	0.000293	0.000817	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL3—Crohn's disease	0.00029	0.00081	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—RASGRP1—Crohn's disease	0.000281	0.000783	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—CXCL8—Crohn's disease	0.000281	0.000783	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—CXCL8—Crohn's disease	0.000281	0.000783	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PLA2G4F—Crohn's disease	0.00028	0.000781	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	0.000279	0.000779	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—JAK2—Crohn's disease	0.000279	0.000779	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—GPR65—Crohn's disease	0.000279	0.000779	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—JAK2—Crohn's disease	0.000279	0.000779	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—STAT3—Crohn's disease	0.000275	0.000767	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ACKR2—Crohn's disease	0.00027	0.000753	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—ITGA4—Crohn's disease	0.000267	0.000744	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SMAD3—Crohn's disease	0.000265	0.000739	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SMAD3—Crohn's disease	0.000265	0.000739	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IL3—Crohn's disease	0.00026	0.000725	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MLN—Crohn's disease	0.000256	0.000714	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—ALB—Crohn's disease	0.000255	0.000713	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CXCL8—Crohn's disease	0.000255	0.000711	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CXCL8—Crohn's disease	0.000255	0.000711	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SOCS1—Crohn's disease	0.000254	0.00071	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—RASGRP1—Crohn's disease	0.000251	0.000702	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	0.000251	0.000701	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL2RA—Crohn's disease	0.000245	0.000685	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL2RA—Crohn's disease	0.000245	0.000685	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	0.000244	0.000682	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—MTMR3—Crohn's disease	0.000238	0.000664	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	0.000237	0.000663	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—GPX4—Crohn's disease	0.000235	0.000654	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TAGAP—Crohn's disease	0.000234	0.000653	CbGpPWpGaD
Orlistat—FASN—Disease—SMAD3—Crohn's disease	0.000222	0.000619	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SMAD3—Crohn's disease	0.00022	0.000613	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RSPO3—Crohn's disease	0.000205	0.000571	CbGpPWpGaD
Orlistat—PNLIP—Disease—TYK2—Crohn's disease	0.000205	0.000571	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL2RA—Crohn's disease	0.000203	0.000567	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCR6—Crohn's disease	0.000199	0.000555	CbGpPWpGaD
Orlistat—PNLIP—Disease—JAK2—Crohn's disease	0.000195	0.000545	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SEL1L—Crohn's disease	0.000194	0.000541	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—FADS1—Crohn's disease	0.000185	0.000517	CbGpPWpGaD
Orlistat—PNLIP—Disease—CD4—Crohn's disease	0.000185	0.000516	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTGS2—Crohn's disease	0.000184	0.000512	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IL2RA—Crohn's disease	0.000182	0.000508	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCR9—Crohn's disease	0.000177	0.000495	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—ALB—Crohn's disease	0.000176	0.000491	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PTGER4—Crohn's disease	0.000175	0.000489	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GPX4—Crohn's disease	0.000174	0.000485	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TYK2—Crohn's disease	0.000173	0.000482	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TYK2—Crohn's disease	0.000173	0.000482	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	0.00017	0.000473	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GCKR—Crohn's disease	0.000168	0.000468	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—JAK2—Crohn's disease	0.000165	0.00046	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GPR65—Crohn's disease	0.000165	0.00046	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—JAK2—Crohn's disease	0.000165	0.00046	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTGS2—Crohn's disease	0.000154	0.000429	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CXCL8—Crohn's disease	0.000151	0.00042	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CXCL8—Crohn's disease	0.000151	0.00042	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL3—Crohn's disease	0.000149	0.000416	CbGpPWpGaD
Orlistat—FASN—Disease—TYK2—Crohn's disease	0.000145	0.000404	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—RASGRP1—Crohn's disease	0.000144	0.000403	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TYK2—Crohn's disease	0.000143	0.0004	CbGpPWpGaD
Orlistat—PNLIP—Disease—STAT3—Crohn's disease	0.000143	0.0004	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL6—Crohn's disease	0.000143	0.000399	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL6—Crohn's disease	0.000143	0.000399	CbGpPWpGaD
Orlistat—FASN—Disease—JAK2—Crohn's disease	0.000138	0.000385	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—JAK2—Crohn's disease	0.000137	0.000381	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—ALB—Crohn's disease	0.000132	0.000367	CbGpPWpGaD
Orlistat—FASN—Disease—CD4—Crohn's disease	0.000131	0.000365	CbGpPWpGaD
Orlistat—FASN—Disease—PTGS2—Crohn's disease	0.00013	0.000363	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CXCL8—Crohn's disease	0.000125	0.000348	CbGpPWpGaD
Orlistat—FASN—Metabolism—ALB—Crohn's disease	0.000124	0.000347	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—JAK2—Crohn's disease	0.000122	0.000342	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—STAT3—Crohn's disease	0.000121	0.000338	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—STAT3—Crohn's disease	0.000121	0.000338	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	0.00012	0.000334	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCR6—Crohn's disease	0.000118	0.000328	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTGS2—Crohn's disease	0.000109	0.000304	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RBX1—Crohn's disease	0.000106	0.000297	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	0.000105	0.000293	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL2RA—Crohn's disease	0.000104	0.000292	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTGER4—Crohn's disease	0.000103	0.000289	CbGpPWpGaD
Orlistat—FASN—Disease—STAT3—Crohn's disease	0.000101	0.000283	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—STAT3—Crohn's disease	0.0001	0.00028	CbGpPWpGaD
Orlistat—PNLIP—Disease—IL6—Crohn's disease	0.0001	0.000279	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—UBE2D1—Crohn's disease	9.32e-05	0.00026	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RIPK2—Crohn's disease	9.04e-05	0.000252	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL3—Crohn's disease	8.81e-05	0.000246	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RASGRP1—Crohn's disease	8.52e-05	0.000238	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL6—Crohn's disease	8.46e-05	0.000236	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL6—Crohn's disease	8.46e-05	0.000236	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SOCS1—Crohn's disease	7.72e-05	0.000215	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—TYK2—Crohn's disease	7.36e-05	0.000205	CbGpPWpGaD
Orlistat—FASN—Disease—IL6—Crohn's disease	7.08e-05	0.000198	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—JAK2—Crohn's disease	7.02e-05	0.000196	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL6—Crohn's disease	7.01e-05	0.000196	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SMAD3—Crohn's disease	6.67e-05	0.000186	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	6.56e-05	0.000183	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCL8—Crohn's disease	6.41e-05	0.000179	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL2RA—Crohn's disease	6.17e-05	0.000172	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MTMR3—Crohn's disease	5.57e-05	0.000156	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ALB—Crohn's disease	5.34e-05	0.000149	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—Crohn's disease	4.67e-05	0.00013	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TYK2—Crohn's disease	4.35e-05	0.000121	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—FADS1—Crohn's disease	4.34e-05	0.000121	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—JAK2—Crohn's disease	4.15e-05	0.000116	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GPX4—Crohn's disease	4.07e-05	0.000113	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GCKR—Crohn's disease	3.93e-05	0.00011	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL8—Crohn's disease	3.79e-05	0.000106	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6—Crohn's disease	3.6e-05	0.0001	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STAT3—Crohn's disease	3.05e-05	8.5e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6—Crohn's disease	2.13e-05	5.94e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALB—Crohn's disease	1.25e-05	3.49e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—Crohn's disease	1.09e-05	3.05e-05	CbGpPWpGaD
